Opioids span a wide range of substances, from compounds harvested directly from the opium poppy to molecules built entirely in a lab and even peptides your own body produces. They are typically grouped into natural opiates, semi-synthetic opioids, fully synthetic opioids, and endogenous opioid peptides, though the boundaries between categories are blurrier than most lists suggest. Understanding which drugs fall where, and why the distinctions matter, helps make sense of everything from prescription pain management to the overdose crisis.
Natural Opiates From the Poppy
The term “opiate” in its strictest sense refers to alkaloids found naturally in the opium poppy, Papaver somniferum. The most familiar are morphine, codeine, and thebaine. Morphine is the prototypical opioid painkiller and the benchmark against which other opioids are measured for potency. Codeine is milder and is commonly found in prescription cough formulations and low-strength pain tablets. Thebaine has little painkilling effect on its own but serves as the raw starting material for several important semi-synthetic drugs.
Opium itself is a crude mixture containing dozens of alkaloids along with sugars, waxes, and other plant material. Papaverine, another opium alkaloid, relaxes smooth muscle but does not act on opioid receptors in the way morphine does, so it is usually discussed separately. These plant-derived compounds all share a complex multi-ring chemical structure known as the phenanthrene skeleton, which is relevant because most fully synthetic opioids abandon that architecture entirely in favor of much simpler molecular shapes.
Researchers have even engineered yeast to produce thebaine and hydrocodone starting from simple sugar, requiring the coordinated expression of more than twenty enzyme activities borrowed from plants, mammals, and bacteria.1PubMed Central. Complete biosynthesis of opioids in yeast That achievement underscores how chemically elaborate the natural opiate biosynthesis pathway really is and hints at future production methods that could bypass poppy cultivation altogether.
Semi-Synthetic Opioids
Semi-synthetic opioids start with a natural opiate molecule and modify it chemically. The result is a drug that retains some structural kinship with morphine but has altered potency, duration, or side-effect profile. The most widely prescribed examples include hydrocodone, oxycodone, hydromorphone, and oxymorphone. Heroin (diacetylmorphine) also belongs to this group: it is simply morphine with two acetyl groups attached, which allows it to cross into the brain faster.
Buprenorphine is a semi-synthetic opioid with unusual pharmacology. It acts as a partial agonist at the mu opioid receptor, meaning it activates the receptor but produces a ceiling effect at higher doses rather than ever-increasing respiratory depression. It also shows antagonist activity at the kappa receptor.2PubMed Central. Buprenorphine: a unique drug with complex pharmacology In animal studies, buprenorphine produces a bell-shaped dose-response curve for pain relief, peaking at a moderate dose and then actually losing effectiveness as the dose climbs further. At those higher doses, it begins to block the effects of full agonists like morphine.3PubMed Central. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions This mixed agonist-antagonist profile is precisely why buprenorphine is used to treat opioid use disorder: it satisfies enough receptor activity to reduce cravings and withdrawal while making it harder for a full agonist to produce a dangerous high on top of it.
Fully Synthetic Opioids
Fully synthetic opioids are designed from scratch rather than derived from the poppy. They tend to be structurally simpler than natural opiates. Several distinct chemical families exist, and the differences between them have real clinical consequences.
Methadone is classified as a diphenylheptane. It acts as a mu opioid receptor agonist much like morphine in terms of the quality of pain relief, but it lasts considerably longer when taken by mouth and has higher oral bioavailability.4PubMed Central. Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations Methadone also blocks the NMDA receptor, a glutamate receptor involved in pain amplification and nerve-injury pain, which makes it useful for neuropathic pain that responds poorly to other opioids.5PubMed Central. Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns
Fentanyl belongs to the phenylpiperidine family and is roughly 50 to 100 times more potent than morphine.4PubMed Central. Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations Other phenylpiperidines include meperidine (sometimes known by the brand name Demerol), alfentanil, sufentanil, and remifentanil. These drugs share a piperidine ring but differ in the chemical groups attached to it, which gives each its unique speed of onset, duration, and metabolism.6Psychosomatics. Pharmacokinetic Drug Interactions of Synthetic Opiate Analgesics Remifentanil, for instance, is broken down so rapidly by blood enzymes that its effects vanish within minutes of stopping an infusion, making it popular in anesthesia where moment-to-moment control matters.
Tramadol sits in its own niche. It binds the mu receptor but also blocks the reuptake of serotonin and norepinephrine, giving it a dual mechanism that is sometimes described as opioid-plus-antidepressant.4PubMed Central. Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations That serotonin activity is why tramadol carries a risk of serotonin syndrome when combined with other serotonergic drugs, a hazard that pure opioid agonists do not share.
Endogenous Opioid Peptides
Your body manufactures its own opioids. These endogenous peptides fall into four families: enkephalins, endorphins, dynorphins, and nociceptin (also called orphanin FQ).7PubMed Central. Endogenous Opioids and Their Role in Stem Cell Biology and Tissue Rescue They act on the same receptors that pharmaceutical opioids target, and they are the reason those receptors exist in the first place. Endorphins are the most culturally famous, loosely associated with “runner’s high” and the pain dampening that kicks in during intense physical stress. Enkephalins are widely distributed in the brain and spinal cord and play a role in modulating everyday pain signals. Dynorphins preferentially activate the kappa receptor and are involved in stress responses and mood regulation, sometimes contributing to feelings of dysphoria rather than euphoria. Nociceptin operates through its own receptor subtype and is involved in pain perception, anxiety, and appetite.
All of these peptides act on the same family of receptors: mu, kappa, delta, and the nociceptin receptor (sometimes called ORL1). These are all members of the large superfamily of G-protein-coupled receptors.8PubMed Central. Molecular mechanisms of opioid receptor-dependent signaling and behavior When activated, they trigger inhibitory signaling inside the cell: calcium channels close, potassium channels open, and the release of pain-signaling neurotransmitters drops. The net effect is that the nerve cell becomes less excitable and pain transmission is dampened.9Cell. Examples of Opioids: Natural, Synthetic, and More Pharmaceutical opioids hijack this system by flooding those same receptors with far more stimulation than the body’s own peptides normally provide.
Emerging Synthetic Opioids and the Potency Problem
The illicit drug supply has introduced compounds that push potency far beyond fentanyl. Carfentanil, originally developed for tranquilizing large animals, is roughly ten times more potent than fentanyl in behavioral assays.10PubMed. Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone Its extreme potency and relatively simple synthesis have made it a dangerous contaminant in street drugs.11PubMed. DARK Classics in Chemical Neuroscience: Carfentanil
More recently, a class called nitazenes (sometimes called benzimidazole opioids) has appeared in overdose cases. Lab testing of nine nitazene analogs found that all of them were more potent than fentanyl at activating the mu receptor’s primary signaling pathway. The most potent, N-desethyl isotonitazene, was about 31 times more potent than fentanyl in those assays.12PubMed Central. In vitro functional profiling of fentanyl and nitazene analogs at the μ-opioid receptor reveals high efficacy for Gi protein signaling These drugs are not approved for any medical use. Their appearance in the drug supply complicates overdose response because standard naloxone doses may be inadequate against compounds of such extreme potency, sometimes requiring repeated doses or higher concentrations.
Opioid-Active Plants Beyond the Poppy
The opium poppy is not the only plant that produces opioid-active compounds. Kratom (Mitragyna speciosa), a tropical tree native to Southeast Asia, contains indole alkaloids that interact with opioid receptors in complex ways. The primary alkaloid, mitragynine, is a partial agonist at the human mu receptor and an antagonist at the kappa and delta receptors.13PubMed Central. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators A more potent oxidized form, 7-hydroxymitragynine, is also a partial mu agonist but with higher potency.
Kratom contains dozens of additional alkaloids, and several of them also have opioid activity. Corynantheidine and mitraciliatine are partial agonists at the mu receptor, while isopaynantheine was identified as the first kratom-derived kappa opioid receptor agonist. Some of these minor alkaloids showed pain relief in mice with reduced respiratory depression compared to morphine.14PubMed Central. Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom This has attracted research interest, though kratom also carries risks of dependence and drug interactions, and it remains unregulated at the federal level in the United States while being controlled in several other countries.15PubMed Central. Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers
Why the Same Opioid Can Affect People Differently
Genetics play a significant role in how a given opioid works in your body. The clearest example involves codeine. Codeine itself is a weak opioid; it must be converted into morphine by a liver enzyme called CYP2D6 to produce meaningful pain relief. People who carry gene variants that make them “poor metabolizers” get very little morphine from a codeine dose, and the drug barely works for them. At the other extreme, “ultrarapid metabolizers” convert codeine to morphine so efficiently that standard doses can push morphine levels into a dangerous range.16PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype
Pharmacokinetic modeling has quantified just how stark the difference is. Ultrarapid metabolizers reach morphine blood concentrations that can cause respiratory depression and have roughly triple the morphine exposure of normal metabolizers after the same codeine dose. Poor metabolizers, meanwhile, get only a small fraction of the morphine exposure that normal metabolizers do.17PubMed Central. Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision Dosing This is not a subtle academic point: it has led to deaths in infants whose breastfeeding mothers were ultrarapid metabolizers taking codeine, and it is the reason clinical pharmacogenetics guidelines now recommend alternative analgesics for people at either metabolic extreme.
Tolerance, Hyperalgesia, and Paradoxical Pain
With repeated opioid use, the body adapts in ways that undermine the drug’s effectiveness. Tolerance, where progressively higher doses are needed to achieve the same effect, involves changes at the receptor level. One mechanism involves a protein called beta-arrestin-2, which plays a role in pulling activated receptors off the cell surface. The relationship is counterintuitive: morphine does not efficiently trigger receptor internalization, yet it produces robust tolerance. Drugs like fentanyl that do trigger internalization may actually allow receptors to recycle back to the surface in a functional state, potentially moderating some aspects of tolerance.18PubMed. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance Recent work confirms that impaired receptor resensitization, driven at least partly by beta-arrestin-2, contributes to the problem in living animals.19PubMed Central. Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons
Even more troubling is opioid-induced hyperalgesia, a state where the drug actually makes you more sensitive to pain rather than less. This is not the same as tolerance, where the drug just stops working as well. In hyperalgesia, pain from a stimulus that would normally be mild gets amplified. Several neural processes are involved, including activation of immune-like cells in the brain and spinal cord (microglia and astrocytes) that ramp up inflammation in the nervous system.20PubMed. Opioid-induced hyperalgesia: Cellular and molecular mechanisms Research has identified specific ion channels called HCN2 in pain-sensing nerves as a key driver of this process: opioid exposure raises a signaling molecule inside these nerve cells, which shifts the behavior of HCN2 channels and causes the nerves to fire more actively.21PubMed Central. Opioid-Induced Hyperalgesia and Tolerance Are Driven by HCN Ion Channels Interestingly, the same study found that tolerance and hyperalgesia are driven by HCN channels in different locations: hyperalgesia by HCN2 in peripheral nerves, and tolerance by HCN channels in the central nervous system. Separate work has implicated the BRAF signaling pathway in pain-sensing neurons as another contributor, linking opioid exposure to hyperactivity of NMDA receptors at spinal cord synapses.22PubMed Central. Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity
Respiratory Depression and Why Opioids Kill
The most dangerous acute effect of opioids is respiratory depression, which is the leading cause of death in overdose. Opioids slow breathing primarily by reducing respiratory rate rather than the depth of each breath. They do this by acting on a cluster of neurons in the brainstem called the preBötzinger Complex, which serves as the body’s core rhythm generator for breathing.23PubMed Central. Multi-Level Regulation of Opioid-Induced Respiratory Depression Specific neurons in this region that express the neurokinin-1 receptor have been identified as the critical site where opioids suppress breathing rate.24Journal of Neuroscience. PreBötzinger Complex Neurokinin-1 Receptor-Expressing Neurons Mediate Opioid-Induced Respiratory Depression The effect is mediated through the mu opioid receptor, which is why mu-selective drugs like fentanyl carry the highest respiratory risk, while kappa-selective compounds are less lethal in this regard.25eLife. Dual mechanisms of opioid-induced respiratory depression in the inspiratory rhythm-generating network
This also explains a critical problem in overdose reversal. Naloxone, the standard rescue drug, works by blocking the mu receptor. But its effect wears off faster than many opioids, especially long-acting ones or ultra-potent synthetics. Nalmefene, a newer alternative, clears from opioid receptors much more slowly: one study measured a clearance half-time from opioid receptors of about 29 hours for nalmefene versus about 2 hours for naloxone.26PubMed. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system That longer receptor occupancy could reduce the risk of re-sedation, which is a real danger when the overdose involves fentanyl or carfentanil.
Animal studies comparing naloxone, naltrexone, nalmefene, and a newer experimental antagonist called MCAM (methocinnamox) found that while all four were equally potent at preventing the effects of buprenorphine and carfentanil, they were dramatically less potent at reversing those effects once they had already taken hold. Naloxone, naltrexone, and nalmefene were at least 31-fold less potent at reversal than at prevention for carfentanil.27PubMed. Comparison of naloxone, naltrexone, nalmefene, and methocinnamox for preventing and reversing the discriminative stimulus effects of buprenorphine and carfentanil in rats discriminating fentanyl from saline In plain terms, it is far easier to block a potent opioid before it binds than to pry it off the receptor afterward.
Peripheral Antagonists for Gut Side Effects
Not all opioid antagonists are designed to reverse overdoses. A class called PAMORAs (peripherally acting mu opioid receptor antagonists) targets one of the most common and persistent side effects of long-term opioid therapy: constipation. Unlike tolerance to pain relief, tolerance to opioid-induced constipation develops poorly or not at all, so the problem persists as long as the drug is taken. PAMORAs are designed to block mu receptors in the gut without crossing the blood-brain barrier, meaning they relieve constipation without interfering with the pain relief happening in the brain. Clinical studies have demonstrated that these agents alleviate constipation while preserving the analgesic effect of the opioid.28PubMed Central. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety Examples include methylnaltrexone, naloxegol, and naldemedine.
Biased Agonism and the Search for Safer Opioids
One of the most active areas in opioid pharmacology is the concept of biased agonism. The idea is straightforward: when a drug activates the mu receptor, it can trigger multiple downstream signaling cascades, and these pathways do not all lead to the same outcomes. The G-protein pathway is primarily responsible for pain relief, while the beta-arrestin pathway has been linked to respiratory depression and constipation.29PubMed Central. Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles If you could design a drug that strongly activates the G-protein pathway while mostly ignoring the beta-arrestin pathway, you might get pain relief with fewer dangerous side effects.
Experimental compounds built on this principle have shown promising results in animal models. One set of compounds showed a strong linear relationship between G-protein signaling bias and a wider safety margin between painkilling doses and doses that suppress breathing.30Cell. Biased Agonism at the Mu-Opioid Receptor Separates Analgesia from Side Effects The real-world picture has proven more complicated, though. One early clinical candidate based on biased agonism, oliceridine, did receive FDA approval but showed a narrower safety advantage than preclinical data had suggested. The hypothesis that beta-arrestin is the sole villain behind respiratory depression has been challenged by studies in beta-arrestin knockout mice that still showed respiratory suppression from opioids.31PubMed Central. Current strategies toward safer mu opioid receptor drugs for pain management The field is still working out which combination of receptor selectivity, signaling bias, and duration of action might eventually produce a genuinely safer strong painkiller.
How Old the Opioid System Really Is
The opioid receptor system is not a quirk of mammalian biology. The four receptor types (mu, kappa, delta, and nociceptin) appear to have arisen from a single ancestral gene through large-scale chromosome duplications early in vertebrate evolution, likely around 450 million years ago, near the origin of jawed vertebrates.32PubMed Central. Evolution of vertebrate opioid receptors Mu opioid receptor sequences have been found across the entire vertebrate tree, from mammals and birds to frogs, bony fish, sharks, and even the Pacific hagfish, one of the most ancient vertebrate lineages. No opioid-receptor-like sequences were detected in any invertebrate species tested.33PubMed. Mu opioid receptor-like sequences are present throughout vertebrate evolution Among the four receptor types, the mu receptor shows evidence of the fastest evolutionary change, suggesting it has been under particular selective pressure.34PubMed Central. The evolution of vertebrate opioid receptors
This deep evolutionary history means that virtually every vertebrate animal with a backbone shares some version of the opioid system. It also explains why opioid drugs, whether natural or synthetic, affect so many body systems at once: the receptors are not confined to pain circuits. They are expressed throughout the brain, spinal cord, gut, immune cells, and other tissues, reflecting hundreds of millions of years of co-option for functions well beyond simple pain control.